scholarly journals Revisiting Role of HbA1c

2021 ◽  
pp. 318-323
Author(s):  
Sanjyoti Panchbudhe ◽  
Shilpa Kumar ◽  
Suresh Babu Kondaveeti
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Influencing Factors ◽  
Reference Range ◽  
Diagnostic Marker ◽  
Glycated Haemoglobin ◽  
Common Occurrence ◽  
Short Term ◽  
Physiological Variations

With the increasing use of HbA1c as a diagnostic marker, more values at the lower end of the reference range can be observed. As more emphasis has been on decreasing and controlling a rising value of glycated haemoglobin, it is currently uncertain how to interpret low HbA1c values. Various conditions not related to diabetes, but with a fairly common occurrence, influence HbA1c. Alternative indices may have to be used for assessing glycemic control in these cases. It is important that such influencing factors are looked into when evaluating an inappropriately or expectantly low HbA1c value. HbA1c is a biomarker that might have utility beyond just diabetes mellitus. Its role needs to be re-examined as it is a test which is widely available, less amenable to short term physiological variations, and can be easily studied. All that is required is a different perspective or approach to its utility.

Effects of long-term optimization and short-term deterioration of glycemic control on glucose counterregulation in type I diabetes mellitus

Diabetes ◽  
1984 ◽  
Vol 33 (4) ◽  
pp. 394-400 ◽  
Author(s):  
G. Bolli ◽  
P. De Feo ◽  
S. De Cosmo ◽  
G. Perriello ◽  
G. Angeletti ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
Short Term

Role of Fibroblast growth factor 21 (FGF-21) as a prognostic marker for fetal and maternal complications in patients with gestational diabetes mellitus

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Mohamed Reda Halawa ◽  
Magdy Hassan Kolaib ◽  
Salah Hussein El-Halawany ◽  
Dina Ahmed Marwan ◽  
Ola Mohamed Mostafa Shaheen
Keyword(s):  
Diabetes Mellitus ◽  
Growth Factor ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Fibroblast Growth Factor ◽  
Prognostic Marker ◽  
Diagnostic Marker ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

Abstract Background Gestational diabetes mellitus (GDM) defined as glucose intolerance with onset or first diagnosis during pregnancy. While GDM usually resolves following delivery, it can have long-lasting health consequences, including increased risk for type 2 diabetes (T2DM) and cardiovascular disease (CVD) in the mother, and future obesity, CVD, T2DM, and/or GDM in the child. This contributes to a vicious intergenerational cycle of obesity and diabetes that impacts the health of the population as a whole. Fibroblast growth factor 21 (FGF21) is a hormone that is expressed predominantly in the liver, but also in other metabolically active tissues such as pancreas, skeletal muscle and adipose tissue. An elevated FGF21 level is also an independent predictor of T2DM. GDM and T2DM are proposed to have similar underlying pathophysiologies, raising the question of whether a similar relationship exists between FGF21 and GDM as it does with T2DM. Objectives assess the role of Fibroblast growth factor 21 (FGF-21) as a prognostic marker for maternal and fetal complications in patients with gestational diabetes mellitus (GDM). Patients and Methods A case control study that was conducted on 50 patients diagnosed with Gestational Diabetes Mellitus and 50 control subjects at Diabetes and Obstetrics outpatient clinic and inpatient ward at Ain Shams university hospitals in the period between December 2018 and July 2019. Patients diagnosed with gestational diabetes mellitus (GDM) at 24-28 weeks of gestation were included in this study. Results FGF 21 levels varied significantly with blood sugar values where higher levels of FGF 21 levels were found in patients with GDM with study results showing that FGF 21 can be used as a diagnostic marker for GDM at levels above 121 pg/ml with sensitivity 84% and specificity 92%. Conclusion FGF 21 can be used as a diagnostic marker for gestational diabetes. Further studies needed for better correlation between FGF 21 levels during pregnancy and maternal outcome.

scholarly journals Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the International Diabetes Management Practices Study (IDMPS)

2020 ◽  
Vol 11 ◽  
pp. 204201882093721
Author(s):  
Ambady Ramachandran ◽  
Sunil M. Jain ◽  
Sagarika Mukherjee ◽  
Sanjeev Phatak ◽  
Shailesh Pitale ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Management Practices ◽  
Diabetes Management ◽  
Diabetes Education ◽  
Glycated Haemoglobin ◽  
Oral Glucose ◽  
Eligibility Criteria ◽  
Cross Sectional ◽  
Glycemic Targets

Objective: To assess the real-world management practices of subjects with type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) in India. Methods: This cross-sectional study was conducted between 7 March 2016 and 15 May 2016 in India as part of the seventh wave (2016) of the International Diabetes Management Practices Study (IDMPS). Adult subjects with T1DM or T2DM visiting physicians during a 2-week recruitment period were included. Results: A total of 55 physicians included 539 subjects who met eligibility criteria. Of 495 subjects with T2DM, 303 were treated with oral glucose lowering drugs (OGLDs) only, 158 were treated with OGLD + insulin, and 27 received insulin only. Among 44 subjects with T1DM receiving insulin, 13 (29.5%) were also treated with OGLD therapy. The most commonly used insulin regimens were basal alone (69/184; 37.5%) and premixed alone (63/184; 34.2%) in subjects with T2DM, and basal + prandial insulin (24/44; 54.5%) in subjects with T1DM. Proportions of subjects achieving glycemic targets were low [glycated haemoglobin (HbA1c) <7%: T1DM = 7.3% (3/44), T2DM = 25.2% (106/495); as targeted by the treating physician: T1DM = 31.8% (14/44), T2DM = 32.1% (59/185); global target: T1DM = 4.8% (2/42) and T2DM = 1.7% (8/482)]. In subjects with T2DM, HbA1c <7% was noted in 11/22 subjects receiving insulin only and 76/260 receiving only OGLDs. Lack of experience in self-managing insulin dosing, poor diabetes education and failure to titrate insulin dosages were the main reasons for non-achievement of glycemic targets. Conclusion: Timely insulinization, education and empowerment of people with diabetes may help improve glycemic control in India.

scholarly journals Diagnosing gestational diabetes mellitus: implications of recent changes in diagnostic criteria and role of glycated haemoglobin (HbA1c)

2017 ◽  
Vol 17 (2) ◽  
pp. 108-113 ◽  
Author(s):  
Fahmy W Hanna ◽  
Christopher J Duff ◽  
Ann Shelley-Hitchen ◽  
Ellen Hodgson ◽  
Anthony A Fryer
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Diagnostic Criteria ◽  
Glycated Haemoglobin

Pulmonary Complications in Diabetes Mellitus: The Role of Glycemic Control

2004 ◽  
Vol 3 (4) ◽  
pp. 455-458 ◽  
Author(s):  
Diego Ardigo ◽  
Silvia Valtuena ◽  
Ivana Zavaroni ◽  
Maria Baroni ◽  
Roberto Delsignore
Keyword(s):  
Diabetes Mellitus ◽  
Glycemic Control ◽  
Pulmonary Complications
Sign in / Sign up

Export Citation Format

Share Document